Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genetic analysis highlights value of germline variants in MDS, AML

Publish date:: September 18, 2019

Key clinical point: Germline DDX41 mutations were found to be relatively prevalent but showed favorable outcomes in a cohort of patients with myelodysplastic syndromes or acute myeloid leukemia.

Major finding: Among 43 unrelated patients, a total of 28 distinct germline DDX41 variants were detected, of which 21 were considered causal.

Study details: A genetic analysis of 1,385 patients with myelodysplastic syndromes or acute myeloid leukemia.

Disclosures: No funding sources were reported, and the authors reported having no conflicts of interest.

Citation:

Sébert M et al. Blood. 2019 Sep 4. doi: 10.1182/blood.2019000909.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,